These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8758470)

  • 21. Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats.
    Silley P; Stephan B; Greife HA; Pridmore A
    J Antimicrob Chemother; 2007 Nov; 60(5):999-1003. PubMed ID: 17872918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
    Nord CE
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of three of the newer quinolones against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria.
    Genzel GH; Stubbings W; Stîngu CS; Labischinski H; Schaumann R
    Int J Antimicrob Agents; 2014 Nov; 44(5):420-3. PubMed ID: 25264128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of DU-6859a against anaerobic bacteria.
    Wexler HM; Molitoris E; Reeves D; Finegold SM
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.
    Kato N; Kato H; Tanaka-Bandoh K; Watanabe K; Ueno K
    J Antimicrob Chemother; 1997 Nov; 40(5):631-7. PubMed ID: 9421310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.
    Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1636-42. PubMed ID: 7492122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
    Goldstein EJ
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S377-81. PubMed ID: 8324151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of Bay Y3118 against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.
    Liebetrau A; Rodloff AC; Behra-Miellet J; Dubreuil L
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3667-71. PubMed ID: 14576144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of DU-6859a, a new potent fluoroquinolone, on fecal microflora in human volunteers.
    Inagaki Y; Yamamoto N; Chida T; Okamura N; Tanaka M
    Jpn J Antibiot; 1995 Mar; 48(3):368-79. PubMed ID: 7752450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients.
    Mikamo H; Sato Y; Hayasaki Y; Kawazoe K; Tamaya T
    Chemotherapy; 1999; 45(3):154-7. PubMed ID: 10224336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro activity of several cytostatic drugs against aerobic and anaerobic intestinal bacteria].
    Vetere A; Giuliano M; Pantosti A; Panichi G
    Boll Ist Sieroter Milan; 1984; 63(6):505-9. PubMed ID: 6534396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Low and High Doses of Marbofloxacin on the Selection of Resistant Enterobacteriaceae in the Commensal Gut Flora of Young Cattle: Discussion of Data from 2 Study Populations.
    Lhermie G; Dupouy V; El Garch F; Ravinet N; Toutain PL; Bousquet-Mélou A; Seegers H; Assié S
    Foodborne Pathog Dis; 2017 Mar; 14(3):152-159. PubMed ID: 28072925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria.
    Fernandes PB; Shipkowitz N; Bower RR; Jarvis KP; Weisz J; Chu DT
    J Antimicrob Chemother; 1986 Dec; 18(6):693-701. PubMed ID: 3818495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.
    MacGowan AP; Bowker KE; Wootton M; Holt HA; Reeves DS
    Antimicrob Agents Chemother; 1998 Feb; 42(2):419-24. PubMed ID: 9527797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the fluoroquinolones on gastrointestinal flora.
    Korten V; Murray BE
    Drugs; 1993; 45 Suppl 3():125-33. PubMed ID: 7689443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of quinolone resistance in anaerobic bacteria.
    Oh H; Edlund C
    Clin Microbiol Infect; 2003 Jun; 9(6):512-7. PubMed ID: 12848726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.